Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

JOURNAL ARTICLE published August 2016 in The Lancet Oncology

Research funded by Dutch Cancer Society, Netherlands (grant number UL2006-4168/CKTO 2006-04) | National Health and Medical Research Council (grant 570894 (2008)) | Italian Medicines Agency (grant number FARM84BCX2) | Canadian Cancer Society Research Institute (grant numbers 015469 and 021039)

Authors: Stephanie M de Boer | Melanie E Powell | Linda Mileshkin | Dionyssios Katsaros | Paul Bessette | Christine Haie-Meder | Petronella B Ottevanger | Jonathan A Ledermann | Pearly Khaw | Alessandro Colombo | Anthony Fyles | Marie-Helene Baron | Henry C Kitchener | Hans W Nijman | Roy F Kruitwagen | Remi A Nout | Karen W Verhoeven-Adema | Vincent T Smit | Hein Putter | Carien L Creutzberg